{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-000927","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.172870+00:00","generated_at":"2026-05-28T04:09:00.548268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ","bullets":["Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).","Full-year 2024 revenue $48.0-48.2M, down 8% YoY; Advanced Energy down 11% to $38.5-38.7M.","OEM revenue Q4 $2.1M (-17% YoY); full-year $9.5M (+6% YoY).","New AYON Body Contouring System expected to launch H2 2025 pending FDA clearance.","CEO cites doubled U.S. generator unit sales in H2 vs H1 and GLP-1-driven demand for skin treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-000927","json":"https://secwatch.observer/filing/0001437749-25-000927.json","markdown":"https://secwatch.observer/filing/0001437749-25-000927.md","text":"https://secwatch.observer/filing/0001437749-25-000927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774925000927/0001437749-25-000927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774925000927/apyx20250110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:09:00.548268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}